stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

AstraZeneca PLC

United Kingdom · LSE: AZN.L · Market cap: · P/E: · P/S:

AstraZeneca makes and sells prescription medicines for cancer, heart and lung disease, vaccines, and rare diseases.

AstraZeneca is a big drugmaker. It discovers, tests, and sells prescription medicines that doctors give to patients — mostly for cancer, heart and circulation problems, lung and breathing diseases, vaccines, and rare illnesses. It doesn't sell to you directly; it sells to hospitals, clinics, pharmacies, and governments, and gets paid when doctors prescribe its drugs.

The business runs on a simple, slow engine. Scientists spend years and enormous sums testing molecules; most fail, and a rare few become blockbuster treatments protected by patents. For a couple of decades those protected drugs earn fat margins, then cheap generic copies arrive and the money fades. So AstraZeneca must constantly refill its pipeline — through its own labs and by buying smaller biotech firms. Its cancer drugs, especially, have become the growth engine, and it has bet heavily on a class of targeted therapies and antibody-drug conjugates that aim at tumors with fewer side effects than old chemotherapy. Its home base is Cambridge, England, but the real map is global: big sales in the United States, China, and Europe. China is a double-edged sword — a huge market and a source of risk, since price cuts and local competition can bite. Rivals include Merck, Pfizer, Roche, and Novartis, all fighting for the same patients and the same doctors. What keeps AstraZeneca in the game is trial data: if a drug keeps patients alive longer, payers will buy it even at a high price.


Drugmaking is cash-hungry. Money goes back into research, into deals to buy promising science, and into dividends for shareholders. The bet is always the same: spend today on molecules that may pay off for years — and accept that many won't.

Saved answer · last researched 15 Nov 2026